According to the announcement of Watson Pharmaceuticals, the company recently received the “Drug Re-Registration Approval Notice” for injectable diacetamidoacetate approved and issued by the Chongqing Drug Administration, agreeing to re-register the above products. The drug approval number is valid until February 20, 2032. This product is suitable for preventing and treating bleeding of various causes. Since it has not been produced for a long time, relevant work must be completed before resuming production, and can only be marketed and sold after on-site inspection and sampling. This approval ensures the normal production and sale of pharmaceuticals, and will not have a significant impact on the company's business performance in the short term.

According to the announcement of Watson Pharmaceuticals, the company recently received the “Drug Re-Registration Approval Notice” for injectable diacetamidoacetate approved and issued by the Chongqing Drug Administration, agreeing to re-register the above products. The drug approval number is valid until February 20, 2032. This product is suitable for preventing and treating bleeding of various causes. Since it has not been produced for a long time, relevant work must be completed before resuming production, and can only be marketed and sold after on-site inspection and sampling. This approval ensures the normal production and sale of pharmaceuticals, and will not have a significant impact on the company's business performance in the short term.